A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
NCT ID: NCT05374512
Last Updated: 2026-01-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
644 participants
INTERVENTIONAL
2022-05-16
2028-11-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
NCT06103864
A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer
NCT06508216
Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer
NCT06954480
A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
NCT06210776
Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In
NCT02708680
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dato-DXd
Arm 1: Dato-DXd
Dato-DXd
Experimental drug. Provided in 100mg vials. IV infusion.
Investigator's Choice of Chemotherapy (ICC)
Arm 2:
If no prior taxane, or prior taxane in the (neo)adjuvant setting and DFI \> 12 months, paclitaxel or nab-paclitaxel
If prior taxane and DFI ≤ 12 months: capecitabine, carboplatin, or eribulin.
Paclitaxel
IV Infusion. Active comparator
Nab-paclitaxel
IV infusion. Active comparator
Carboplatin
IV infusion. Active comparator
Capecitabine
Tablet. Oral route of administration. Active comparator
Eribulin mesylate
IV infusion. Active comparator
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dato-DXd
Experimental drug. Provided in 100mg vials. IV infusion.
Paclitaxel
IV Infusion. Active comparator
Nab-paclitaxel
IV infusion. Active comparator
Carboplatin
IV infusion. Active comparator
Capecitabine
Tablet. Oral route of administration. Active comparator
Eribulin mesylate
IV infusion. Active comparator
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Participant must be ≥ 18 years at the time of screening. Type of Participant and Disease Characteristics
2. Histologically or cytologically documented locally recurrent inoperable TNBC, which cannot be treated with curative intent, or metastatic TNBC. TNBC is defined as:
* Negative for ER with \< 1% of tumour cells positive for ER on IHC.
* Negative for progesterone receptor with \< 1% of tumour cells positive for progesterone receptor on IHC.
* Negative for HER2 with 0 or 1+ intensity on IHC or 2+ intensity on IHC and negative by in situ hybridisation per the ASCO-CAP HER2 guideline
3. No prior chemotherapy or other systemic anti-cancer therapy for metastatic or locally recurrent inoperable breast cancer.
4. Not a candidate for PD-1/PD-L1 inhibitor therapy, defined as:
* Participants whose tumours are PD-L1-negative, or
* Participants whose tumours are PD-L1-positive and have:
1. relapsed after prior PD-1/PD-L1 inhibitor therapy for early-stage breast cancer,
2. comorbidities precluding PD-1/PD-L1 inhibitor therapy, or
3. no regulatory access to pembrolizumab \[participant's country does not have regulatory approval at the time of screening\]).
5. At least 1 measurable lesion not previously irradiated that qualifies as a RECIST 1.1 TL at baseline and can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes, which must have short axis ≥ 15 mm) with computed tomography (CT) or magnetic resonance imaging (MRI), and is suitable for accurate repeated measurements.
6. ECOG PS 0 or 1 with no deterioration over the previous 2 weeks prior to baseline or day of first dosing.
7. Eligible for one of the chemotherapy options listed as ICC (paclitaxel, nab-paclitaxel, capecitabine, carboplatin, or eribulin), based on DFI and prior taxane exposure, per investigator assessment.
8. Has had an adequate treatment washout period before Cycle 1 Day 1, defined as:
* Major surgery: ≥ 3 weeks.
* Radiation therapy including palliative radiation to chest: ≥ 4 weeks (palliative radiation therapy to other areas ≥ 2 weeks).
* Corticosteroid therapy for central nervous system metastatic disease: \> 3 days.
* Anti cancer therapy including hormonal therapy: ≥ 3 weeks (for small molecule targeted agents: ≥ 2 weeks or 5 half-lives, whichever is longer).
* Nitrosoureas or mitomycin C: ≥ 6 weeks.
* Antibody-based anti cancer therapy: ≥ 4 weeks with the exception of receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitors (eg, denosumab for the treatment of bone metastases).
* Immunotherapy (non-antibody-based therapy), retinoid therapy: ≥ 2 weeks or 5 times the terminal elimination half-life of the agent, whichever is longer.
* Chloroquine/hydroxychloroquine: \> 14 days.
9. Written confirmation of tumour sample needs to be available prior to enrolment and tumour samples should be available prior to randomisation. All participants must have a FFPE metastatic (excluding bone) or locally recurrent inoperable tumour sample (block preferred, or a minimum of 20 freshly cut slides) available, collected ≤ 3 months prior to screening. If neither an adequate FFPE block nor the minimum of 20 slides are available from the most recent biopsy, or if a biopsy is not feasible for safety reasons, and this is clearly documented, an archival tumour specimen obtained before the diagnosis of locally recurrent inoperable or metastatic breast cancer may be submitted, pending approval by the Global Study Team.
10. Participants with a history of previously treated neoplastic spinal cord compression or asymptomatic, stable brain metastases, who require no treatment with corticosteroids or anticonvulsants may be included in the study, if they are no longer symptomatic and have recovered from acute toxic effects of radiotherapy. A minimum of 2 weeks must have elapsed between the end of radiotherapy and Cycle 1 Day 1. A minimum of 3 days must have elapsed between the end of corticosteroid therapy for central nervous system metastatic disease and Cycle 1 Day 1.
11. Adequate organ and bone marrow function within 7 days before randomisation as follows:
* Haemoglobin ≥ 9.0 g/dL (red blood cell/plasma transfusion is not allowed within 1 week prior to screening assessment).
* Absolute neutrophil count ≥ 1.5 × 10\^9/L (granulocyte colony stimulating factor administration is not allowed within 1 week prior to screening assessment).
* Platelet count ≥ 100 × 10\^9/L (platelet transfusion is not allowed within 1 week prior to screening assessment).
* Total bilirubin (TBL) ≤ 1.5 × upper limit of normal (ULN) or \< 3 × ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinemia).
* Except in the setting of HBV, Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN for AST/ALT (\< 5 × ULN in participants with liver metastases). See Exclusion Criterion 5 for requirements in the setting of HBV.
* Calculated CrCL ≥ 30 mL/minute as determined by Cockcroft Gault
12. Minimum life expectancy of 12 weeks.
Sex
13. Male or female. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Reproduction
14. Negative pregnancy test (serum) for women of childbearing potential.
15. Female participants must be at least 1 year post-menopausal, surgically sterile, or using at least 1 highly effective form of birth control (a highly effective method of contraception is defined as one that can achieve a failure rate of less than 1% per year when used consistently and correctly.) Women of childbearing potential who are sexually active with a non sterilised male partner must agree to use at least 1 highly effective method of birth control. They should have been stable on their chosen method of birth control for a minimum of 3 months before Cycle 1 Day 1 and continue for at least 7 months after the last dose. Female participants must refrain from egg cell donation or retrieval for their own use, and breastfeeding from enrolment throughout the study and for at least 7 months after the last dose of study drug. Any non sterilised male partner of a woman of childbearing potential must use a male condom plus spermicide (condom alone in countries where spermicides are not approved) throughout this period.
16. Male participants who intend to be sexually active with a female partner of childbearing potential must be surgically sterile or use an acceptable method of contraception from the time of screening throughout the total duration of the study and the drug washout period (at least 6 months after the last dose of study intervention), in addition to the female partner using a highly effective contraceptive method, to prevent pregnancy in a partner. Male participants must not donate or bank sperm during this same time period. Preservation of sperm should be considered prior to randomisation. Not engaging in heterosexual activity (sexual abstinence) for the duration of the study and drug washout period is an acceptable practice, if this is the preferred usual lifestyle of the participant. Periodic or occasional abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception.
Informed Consent
17. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
18. Provision of signed and dated written Optional Genetic Research Information informed consent prior to collection of sample for optional genetic research that supports Genomic Initiative.
Exclusion Criteria
1. As judged by the investigator, any evidence of diseases (such as severe or uncontrolled systemic diseases, uncontrolled hypertension, history of allogeneic organ transplant, and active bleeding diseases, ongoing or active infection, or significant cardiac or psychological conditions), and/or substance abuse which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardise compliance with the protocol.
2. History of another primary malignancy except for malignancy treated with curative intent with no known active disease within 3 years before the first dose of study intervention and of low potential risk for recurrence (per investigator assessment). Exceptions include adequately resected non-melanoma skin cancer (basal cell carcinoma of the skin or squamous cell carcinoma of the skin) and curatively treated in situ disease.
3. Persistent toxicities caused by previous anti-cancer therapy, excluding alopecia, not yet improved to Grade ≤ 1 or baseline. Participants with irreversible toxicity that is not reasonably expected to be exacerbated by study intervention in the opinion of the investigator may be included (eg, hearing loss).
4. Uncontrolled infection requiring IV antibiotics, antivirals or antifungals; suspected infections (eg, prodromal symptoms); or inability to rule out infections (participants with localised fungal infections of skin or nails are eligible).
5. Known active or uncontrolled hepatitis B or C virus infection.
6. Known human immunodeficiency virus (HIV) infection that is not well controlled. All of the following criteria are required to define an HIV infection that is well controlled: undetectable viral RNA, cluster of differentiation (CD)4+ count \> 350 cells/mm3, no history of an acquired immune deficiency syndrome-defining opportunistic infection within the past 12 months, and stable for at least 4 weeks on the same anti-HIV medications.
7. Uncontrolled or significant cardiac disease including:
* Myocardial infarction or uncontrolled/unstable angina within 6 months prior to Cycle 1 Day 1
* Congestive heart failure (New York Heart Association Class II to IV), or
* Uncontrolled or significant cardiac arrhythmia, or
* Uncontrolled hypertension (resting systolic blood pressure \> 180 mmHg or diastolic blood pressure \> 110 mmHg).
8. Resting ECG with clinically abnormal findings.
9. Uncontrolled hypercalcaemia: \> 1.5 mmol/L (\> 6 mg/dL) ionised calcium, or serum calcium (uncorrected for albumin) \> 3 mmol/L (\> 12 mg/dL), or corrected serum calcium \> ULN, or clinically significant (symptomatic) hypercalcaemia.
10. History of non-infectious ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening
11. Has severe pulmonary function compromise.
12. Leptomeningeal carcinomatosis.
13. Clinically significant corneal disease.
14. Known active tuberculosis infection (clinical evaluation that may include clinical history, physical examination and radiographic findings, or tuberculosis testing in line with local practice).
Prior/Concomitant Therapy
15. Prior exposure to:
* Any treatment (including ADC) containing a chemotherapeutic agent targeting topoisomerase I
* TROP2-targeted therapy
* Prior treatment with same ICC agent
* Chloroquine/hydroxychloroquine without an adequate treatment washout period of \> 14 days prior to randomisation.
16. Any concurrent anti cancer treatment.
17. Concurrent use of systemic hormone replacement therapy (HRT; eg, oestrogen and progesterone). However, concurrent use of hormones for other non-cancer-related conditions (eg, insulin for diabetes or levothyroxine for hypothyroidism) is acceptable.
18. Major surgical procedure (excluding placement of vascular access) or significant traumatic injury within 3 weeks of the first dose of study intervention or an anticipated need for major surgery during the study.
19. Receipt of live, attenuated vaccine within 30 days prior to the first dose of study treatment.
20. Concomitant use of chronic systemic (IV or oral) corticosteroids or other immunosuppressive medications except for managing AEs (inhaled steroids or intra articular steroid injections are permitted in this study).
Prior/Concurrent Clinical Study Experience
21. Previous randomisation in the present study.
22. Participation in another clinical study with a study intervention or investigational medicinal device administered in the last 4 weeks prior to first dose of study intervention (unless the safety profile is known prior to randomisation), randomisation into a prior T-DXd or Dato DXd study regardless of treatment assignment, or concurrent enrolment in another clinical study, unless it is an observational (non interventional) clinical study or during the follow-up period of an interventional study.
23. Participants with a known history of severe hypersensitivity reactions to either the drug or any excipients (including but not limited to polysorbate 80) of Dato-DXd or ICC.
24. Known history of severe hypersensitivity reactions to other monoclonal antibodies.
Other Exclusions
25. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
26. Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions and requirements.
27. Currently pregnant (confirmed with positive pregnancy test) or breast feeding or planning to become pregnant.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Daiichi Sankyo
INDUSTRY
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Duarte, California, United States
Research Site
Los Angeles, California, United States
Research Site
San Francisco, California, United States
Research Site
Grand Junction, Colorado, United States
Research Site
Longmont, Colorado, United States
Research Site
New Haven, Connecticut, United States
Research Site
Washington D.C., District of Columbia, United States
Research Site
Miami, Florida, United States
Research Site
Miami, Florida, United States
Research Site
Atlanta, Georgia, United States
Research Site
Louisville, Kentucky, United States
Research Site
Detroit, Michigan, United States
Research Site
Albuquerque, New Mexico, United States
Research Site
New York, New York, United States
Research Site
Charlotte, North Carolina, United States
Research Site
Winston-Salem, North Carolina, United States
Research Site
Providence, Rhode Island, United States
Research Site
Sioux Falls, South Dakota, United States
Research Site
Memphis, Tennessee, United States
Research Site
Nashville, Tennessee, United States
Research Site
Fort Worth, Texas, United States
Research Site
Houston, Texas, United States
Research Site
Kingwood, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
Charlottesville, Virginia, United States
Research Site
Spokane Valley, Washington, United States
Research Site
Madison, Wisconsin, United States
Research Site
Buenos Aires, , Argentina
Research Site
Buenos Aires, , Argentina
Research Site
CABA, , Argentina
Research Site
CABA, , Argentina
Research Site
Ciudad Autónoma Buenos Aires, , Argentina
Research Site
Ciudad de Buenos Aires, , Argentina
Research Site
Mar del Plata, , Argentina
Research Site
Rosario, , Argentina
Research Site
Anderlecht, , Belgium
Research Site
Ghent, , Belgium
Research Site
Namur, , Belgium
Research Site
Sint-Niklaas, , Belgium
Research Site
Wilrijk, , Belgium
Research Site
Brasília, , Brazil
Research Site
Curitiba, , Brazil
Research Site
Goiânia, , Brazil
Research Site
Jaú, , Brazil
Research Site
Porto Alegre, , Brazil
Research Site
Porto Alegre, , Brazil
Research Site
Rio de Janeiro, , Brazil
Research Site
São Paulo, , Brazil
Research Site
São Paulo, , Brazil
Research Site
São Paulo, , Brazil
Research Site
Calgary, Alberta, Canada
Research Site
Barrie, Ontario, Canada
Research Site
Hamilton, Ontario, Canada
Research Site
Ottawa, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Greenfield Park, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Québec, Quebec, Canada
Research Site
Beijing, , China
Research Site
Beijing, , China
Research Site
Beijing, , China
Research Site
Bengbu, , China
Research Site
Changchun, , China
Research Site
Changsha, , China
Research Site
Changsha, , China
Research Site
Chengdu, , China
Research Site
Chongqing, , China
Research Site
Guangzhou, , China
Research Site
Guangzhou, , China
Research Site
Hangzhou, , China
Research Site
Hangzhou, , China
Research Site
Hangzhou, , China
Research Site
Hefei, , China
Research Site
Hefei, , China
Research Site
Jinan, , China
Research Site
Jinan, , China
Research Site
Nanchang, , China
Research Site
Nanjing, , China
Research Site
Shanghai, , China
Research Site
Shanghai, , China
Research Site
Shenyang, , China
Research Site
Shenzhen, , China
Research Site
Tianjin, , China
Research Site
Xi'an, , China
Research Site
Xi'an, , China
Research Site
Zhengzhou, , China
Research Site
Zhengzhou, , China
Research Site
Bordeaux, , France
Research Site
Dijon, , France
Research Site
Limoges, , France
Research Site
Lyon, , France
Research Site
Marseille, , France
Research Site
Montpellier, , France
Research Site
Paris, , France
Research Site
Rouen, , France
Research Site
Saint-Herblain, , France
Research Site
Tours, , France
Research Site
Aschaffenburg, , Germany
Research Site
Bonn, , Germany
Research Site
Frankfurt am Main, , Germany
Research Site
Georgsmarienhütte, , Germany
Research Site
Hanover, , Germany
Research Site
Heilbronn, , Germany
Research Site
Koblenz Am Rhein, , Germany
Research Site
Langen, , Germany
Research Site
München, , Germany
Research Site
Münster, , Germany
Research Site
Wiesbaden, , Germany
Research Site
Budapest, , Hungary
Research Site
Budapest, , Hungary
Research Site
Miskolc, , Hungary
Research Site
Nyíregyháza, , Hungary
Research Site
Zalaegerszeg, , Hungary
Research Site
Bangalore, , India
Research Site
Jaipur, , India
Research Site
Kolkata, , India
Research Site
Nagpur, , India
Research Site
Nashik, , India
Research Site
New Delhi, , India
Research Site
Puducherry, , India
Research Site
Vadodara, , India
Research Site
Borgo San Lorenzo, , Italy
Research Site
Catanzaro, , Italy
Research Site
Genova, , Italy
Research Site
Livorno, , Italy
Research Site
Macerata, , Italy
Research Site
Milan, , Italy
Research Site
Milan, , Italy
Research Site
Modena, , Italy
Research Site
Napoli, , Italy
Research Site
Roma, , Italy
Research Site
Rozzano, , Italy
Research Site
Chūōku, , Japan
Research Site
Fukushima, , Japan
Research Site
Hiroshima, , Japan
Research Site
Isehara-shi, , Japan
Research Site
Kagoshima, , Japan
Research Site
Kashiwa, , Japan
Research Site
Kitaadachi-gun, , Japan
Research Site
Kōtoku, , Japan
Research Site
Kyoto, , Japan
Research Site
Matsuyama, , Japan
Research Site
Nagoya, , Japan
Research Site
Nagoya, , Japan
Research Site
Niigata, , Japan
Research Site
Nishinomiya-shi, , Japan
Research Site
Sendai, , Japan
Research Site
Shinagawa-ku, , Japan
Research Site
Shinjuku-ku, , Japan
Research Site
Tsukuba, , Japan
Research Site
Yokohama, , Japan
Research Site
CD Mexico, , Mexico
Research Site
Guadalajara, , Mexico
Research Site
Guadalajara Jalisco, , Mexico
Research Site
Mexico City, , Mexico
Research Site
México, , Mexico
Research Site
México, , Mexico
Research Site
Bacolod, , Philippines
Research Site
Cebu, , Philippines
Research Site
Cebu City, , Philippines
Research Site
City of Muntinlupa, , Philippines
Research Site
Iloilo City, , Philippines
Research Site
Quezon City, , Philippines
Research Site
Quezon City, , Philippines
Research Site
San Juan City, , Philippines
Research Site
Bialystok, , Poland
Research Site
Bydgoszcz, , Poland
Research Site
Lodz, , Poland
Research Site
Skórzewo, , Poland
Research Site
Warsaw, , Poland
Research Site
Wroclaw, , Poland
Research Site
Bukit Merah, , Singapore
Research Site
Singapore, , Singapore
Research Site
Singapore, , Singapore
Research Site
Cape Town, , South Africa
Research Site
Johannesburg, , South Africa
Research Site
Pretoria, , South Africa
Research Site
Pretoria, , South Africa
Research Site
Soweto, , South Africa
Research Site
Busan, , South Korea
Research Site
Daegu, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Barcelona, , Spain
Research Site
Barcelona, , Spain
Research Site
Granada, , Spain
Research Site
L'Hospitalet de Llobregat, , Spain
Research Site
Madrid, , Spain
Research Site
Madrid, , Spain
Research Site
Madrid, , Spain
Research Site
Majadahonda, , Spain
Research Site
Málaga, , Spain
Research Site
Santiago de Compostela, , Spain
Research Site
Seville, , Spain
Research Site
Hsinchu, , Taiwan
Research Site
Taichung, , Taiwan
Research Site
Taichung, , Taiwan
Research Site
Tainan, , Taiwan
Research Site
Tainan, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Taoyuan District, , Taiwan
Research Site
Bangkok, , Thailand
Research Site
Bangkok, , Thailand
Research Site
Bangkok, , Thailand
Research Site
Chiang Mai, , Thailand
Research Site
Dusit, , Thailand
Research Site
Hat Yai, , Thailand
Research Site
Khon Kaen, , Thailand
Research Site
Ankara, , Turkey (Türkiye)
Research Site
Ankara, , Turkey (Türkiye)
Research Site
Diyarbakır, , Turkey (Türkiye)
Research Site
Istanbul, , Turkey (Türkiye)
Research Site
Izmir, , Turkey (Türkiye)
Research Site
Konya, , Turkey (Türkiye)
Research Site
Malatya, , Turkey (Türkiye)
Research Site
Bristol, , United Kingdom
Research Site
Cardiff, , United Kingdom
Research Site
Edinburgh, , United Kingdom
Research Site
London, , United Kingdom
Research Site
London, , United Kingdom
Research Site
London, , United Kingdom
Research Site
Northampton, , United Kingdom
Research Site
Nottingham, , United Kingdom
Research Site
Warwick, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Dent RA, Cescon DW, Bachelot T, Jung KH, Shao ZM, Saji S, Traina TA, Vukovic P, Mapiye D, Maxwell MJ, Schmid P, Cortes J. TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer. Future Oncol. 2023 Nov;19(35):2349-2359. doi: 10.2217/fon-2023-0228. Epub 2023 Aug 1.
Related Links
Access external resources that provide additional context or updates about the study.
Description: Breast Cancer Study Locator details (for US)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-509260-25
Identifier Type: REGISTRY
Identifier Source: secondary_id
2021-005223-21
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
D926PC00001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.